Can tracking a precancerous condition slash myeloma diagnosis delays?
NCT ID NCT05539079
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This study follows 2,000 people with monoclonal gammopathy of undetermined significance (MGUS), a condition that can precede multiple myeloma, a rare blood cancer. The goal is to measure how often MGUS progresses to myeloma and to understand current monitoring practices. Participants will complete annual questionnaires for up to five years, and some will provide blood samples. The findings could lead to better screening and earlier diagnosis of myeloma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve early detection of myeloma by clarifying how MGUS progresses and how it should be monitored, potentially reducing diagnostic delays.
- What could go wrong
- This is an observational study, so it won't test a treatment. Results depend on long-term follow-up and may not change clinical practice immediately.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MGUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Secure Study
RECRUITINGOxford, Oxfordshire, OX3 7LE, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.